Shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) have received a consensus rating of “Hold” from the nine analysts that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $7.00.

A number of research analysts recently issued reports on the stock. ValuEngine downgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday. Zacks Investment Research downgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday. Stifel Nicolaus decreased their price target on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a research note on Wednesday, November 8th. BidaskClub upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Finally, Maxim Group set a $9.00 price target on shares of Keryx Biopharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, July 27th.

A number of hedge funds have recently added to or reduced their stakes in the business. UBS Asset Management Americas Inc. raised its holdings in Keryx Biopharmaceuticals by 0.3% during the second quarter. UBS Asset Management Americas Inc. now owns 38,316 shares of the biopharmaceutical company’s stock worth $277,000 after purchasing an additional 102 shares in the last quarter. Legal & General Group Plc raised its holdings in Keryx Biopharmaceuticals by 1.2% during the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 300 shares in the last quarter. Rhumbline Advisers raised its holdings in Keryx Biopharmaceuticals by 0.3% during the second quarter. Rhumbline Advisers now owns 99,711 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 335 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Keryx Biopharmaceuticals by 4.2% during the second quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 590 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Keryx Biopharmaceuticals by 1.0% during the first quarter. Bank of America Corp DE now owns 108,558 shares of the biopharmaceutical company’s stock worth $669,000 after purchasing an additional 1,058 shares in the last quarter. 65.44% of the stock is currently owned by institutional investors.

Keryx Biopharmaceuticals (NASDAQ KERX) traded down $0.08 during midday trading on Monday, hitting $4.83. 3,248,500 shares of the stock traded hands, compared to its average volume of 1,508,571. Keryx Biopharmaceuticals has a twelve month low of $4.47 and a twelve month high of $8.38. The company has a quick ratio of 3.76, a current ratio of 4.46 and a debt-to-equity ratio of 13.95.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 323.92%. The firm had revenue of $15.00 million during the quarter, compared to analysts’ expectations of $18.88 million. During the same quarter in the prior year, the firm earned ($0.39) EPS. The firm’s revenue was up 138.1% compared to the same quarter last year. equities research analysts anticipate that Keryx Biopharmaceuticals will post -1.34 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/13/keryx-biopharmaceuticals-inc-kerx-receives-average-rating-of-hold-from-analysts.html.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.